357 related articles for article (PubMed ID: 7775601)
1. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells.
Ram TG; Kokeny KE; Dilts CA; Ethier SP
J Cell Physiol; 1995 Jun; 163(3):589-96. PubMed ID: 7775601
[TBL] [Abstract][Full Text] [Related]
2. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
[TBL] [Abstract][Full Text] [Related]
5. Growth factor-independent proliferation of rat mammary carcinoma cells by autocrine secretion of neu-differentiation factor/heregulin and transforming growth factor-alpha.
Ethier SP; Langton BC; Dilts CA
Mol Carcinog; 1996 Feb; 15(2):134-43. PubMed ID: 8599580
[TBL] [Abstract][Full Text] [Related]
6. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
[TBL] [Abstract][Full Text] [Related]
8. ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes.
Marikovsky M; Lavi S; Pinkas-Kramarski R; Karunagaran D; Liu N; Wen D; Yarden Y
Oncogene; 1995 Apr; 10(7):1403-11. PubMed ID: 7731691
[TBL] [Abstract][Full Text] [Related]
9. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
10. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas.
Balañá ME; Lupu R; Labriola L; Charreau EH; Elizalde PV
Oncogene; 1999 Nov; 18(46):6370-9. PubMed ID: 10597237
[TBL] [Abstract][Full Text] [Related]
11. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX
Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840
[TBL] [Abstract][Full Text] [Related]
12. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
Bacus SS; Yarden Y; Oren M; Chin DM; Lyass L; Zelnick CR; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli RR; Hynes NE; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K
Oncogene; 1996 Jun; 12(12):2535-47. PubMed ID: 8700512
[TBL] [Abstract][Full Text] [Related]
13. Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells.
Marte BM; Jeschke M; Graus-Porta D; Taverna D; Hofer P; Groner B; Yarden Y; Hynes NE
Mol Endocrinol; 1995 Jan; 9(1):14-23. PubMed ID: 7760847
[TBL] [Abstract][Full Text] [Related]
14. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
15. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
16. NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells.
Marte BM; Graus-Porta D; Jeschke M; Fabbro D; Hynes NE; Taverna D
Oncogene; 1995 Jan; 10(1):167-75. PubMed ID: 7824269
[TBL] [Abstract][Full Text] [Related]
17. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
18. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.
Schaefer G; Fitzpatrick VD; Sliwkowski MX
Oncogene; 1997 Sep; 15(12):1385-94. PubMed ID: 9333014
[TBL] [Abstract][Full Text] [Related]
19. Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells.
Mincione G; Piccirelli A; Lazzereschi D; Salomon DS; Colletta G
J Cell Physiol; 1998 Aug; 176(2):383-91. PubMed ID: 9648926
[TBL] [Abstract][Full Text] [Related]
20. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
Daly JM; Jannot CB; Beerli RR; Graus-Porta D; Maurer FG; Hynes NE
Cancer Res; 1997 Sep; 57(17):3804-11. PubMed ID: 9288791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]